









Markets
/
Stocks
/
nasdaq-naii
/

Natural Alternatives International Inc

NAII

2.980USD

+0.250+9.16%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

18.41MMarket Cap

LossP/E TTM



Natural Alternatives International Inc

2.980

+0.250+9.16%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Natural Alternatives International Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Natural Alternatives International Inc's Score

Industry at a Glance

Industry Ranking

125 / 159

Overall Ranking

414 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Natural Alternatives International Inc Highlights

StrengthsRisks

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.

Fairly Valued

The company’s latest PE is -1.20, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.06M shares, decreasing 4.12% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 297.66K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.44, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 33.87M, representing a year-over-year increase of 14.84%, while its net profit experienced a year-over-year increase of 285.06%.

Score

Industry at a Glance

Previous score

6.44

Change



Financials

6.03

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.97

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.73

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.22

Key Metrics

Free cash flow

No Data

Natural Alternatives International Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.17, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -1.20, which is -4617.07% below the recent high of 54.02 and -915.41% above the recent low of -12.14.

Score

Industry at a Glance

Previous score

8.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 125/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.77.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.05, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 3.01 and the support level at 2.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.29

Change

-0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.084

Neutral

RSI(14)

58.018

Neutral

STOCH(KDJ)(9,3,3)

51.643

Buy

ATR(14)

0.189

High Vlolatility

CCI(14)

152.704

Buy

Williams %R

20.408

Buy

TRIX(12,20)

-0.259

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.779

Buy

MA10

2.776

Buy

MA20

2.734

Buy

MA50

3.014

Sell

MA100

3.289

Sell

MA200

3.409

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 33.41%, representing a quarter-over-quarter decrease of 39.07%. The largest institutional shareholder is James Simons, holding a total of 297.66K shares, representing 4.82% of shares outstanding, with 3.41% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

LeDoux (Mark A)

962.54K

-0.61%

Dimensional Fund Advisors, L.P.

426.29K

-0.53%

Caldwell Sutter Capital, Inc

419.45K

-0.34%

Renaissance Technologies LLC

Star Investors

297.66K

-2.14%

Mink Brook Asset Management LLC

293.98K

-0.32%

The Vanguard Group, Inc.

Star Investors

243.06K

Wolf (Kenneth Eugene)

131.99K

-5.42%

Morgan Stanley Smith Barney LLC

117.50K

+25.60%

Bridgeway Capital Management, LLC

111.28K

-7.46%

Dunn (Alan G)

91.21K

+9.61%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.89, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.